Avalo Therapeutics Grants Inducement Equity Awards to New Employees
News related to:Avalo Therapeutics · 1 min read
WAYNE, Pa., Sept. 29, 2026 /CourierPR/ -- Avalo Therapeutics, a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, has announced the grant of inducement equity awards to three new employees. The company’s Compensation Committee approved the grants of nonstatutory stock options to purchase an aggregate of 101,600 shares of common stock, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted on September 25, 2026, with an exercise price of $15.47 per share, equivalent to the closing price of Avalo’s common stock on the grant date. These options will vest as follows: 25% of the underlying shares will vest on the one-year anniversary of the applicable employee’s start date, with the remaining shares vesting monthly over the next 36 months, subject to the employees’ continued service with the company. The options are subject to the terms and conditions of Avalo’s 2025 Inducement Award Plan and award agreements thereunder.
Avalo Therapeutics is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program for hidradenitis suppurativa (HS), a chronic inflammatory skin condition affecting an estimated 1-4% of the global population. The company is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb, as part of its broader therapeutic portfolio.
In a forward-looking statement, Avalo Therapeutics noted that its expansion into new talent through inducement equity awards is a strategic move to support the company’s growth and development. The company’s commitment to developing innovative treatments for immune-mediated inflammatory diseases remains a key focus.
The press release also included a disclaimer regarding forward-looking statements, noting that such statements are subject to significant risks and uncertainties. Avalo Therapeutics encourages investors and readers to review the full text of the forward-looking statements for a complete understanding of the potential risks and uncertainties associated with the company’s operations and future prospects.